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Abstract
The study objective was to analyse the effect of the herbal drug Canephron N, namely, its ability to potentiate the efficacy 
of extracorporeal shock wave lithotripsy (ESWL) in the treatment of patients with urolithiasis (UL) and prevent recurrence of stone 
formation.
Aim. To сheck the hypothesis that treatment with Canephron N can potentiate lithotripsy and reduce the risk of re-stone 
formation. 
Methodology. Patients at the age of 18 to 65 years had calcium oxalate urolithiasis with the size of the stone from 0.8 to 
1.3 cm in the kidneys and from 0.5 to 0.9 cm. in ureters who underwent ESWL procedure. They were randomized into 2 equal groups 
of 30 people. The treatment group received general recommendations on the management of the patient with UL following ESWL 
and the herbal drug Canephron N for 6 months. The control group received only general recommendations. Moreover, according to 
condition, both groups received painkillers and spasmolytics if pain occurred during elimination of fragments. The following param-
eters were evaluated: the period of elimination of fragments after stone disintegration by ESWL method; the percentage of complete 
elimination of fragments; the presence of pain syndrome and leukocyturia in the postoperative period; the rate of recurrence of stone 
formation during one year after the procedure.
Results. More complete and rapid elimination of fragments was observed in the treatment group. Thus, up to day 14 elimi-
nation of stone fragments was observed in 96.6 % of patients in the treatment group versus 76.6 % in the control group. Fewer cases 
of pain syndrome during elimination of stone fragments (23 % in the treatment group and 43 % in the control group) and rare cases 
of leukocyturia within 14 days (10 % versus 23 %, respectively) were observed in the treatment group. Recurrent stone formation 
within the year was not observed in patients of the treatment group, in the control group – in 23 % of patients. However, because of 
the small size of the groups, one may talk about a tendency but not about statistically significant patterns.
Conclusion. Canephron N is an effective and safe drug in the treatment of patients with urolithiasis who underwent extracor-
poreal shock wave lithotripsy. Its use contributes to more rapid and safe elimination of fragments of destructed calculi and reduces 
risk of recurrent stone formation.
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1. Introduction
Urolithiasis (UL) is a metabolic disease caused by a variety of endogenous and/or exoge-
nous factors; it is often hereditary and characterized by stone formation in the urinary system [1]. 
Despite major advances in early diagnosing and treatment of patients with UL [2, 3], the patient 
stream to hospitals is only increased [4] every year due to the lack of consistency between the 
inpatient and outpatient urological services. Moreover, the development of metaphylaxis methods 
of recurrent stone formation falls far behind the introduction of new methods of calculi removal 
from the urinary tracts. This tendency is the least efficient from economic point of view because 
the mechanical stone removal does not solve the problems of metabolic disorders that lead to stone 
formation. The recurrence rate of urolithiasis after removing calculi is 30 %. Therefore, economic 
aspects are important and discussed at present [1, 3].
Extracorporeal shock wave lithotripsy (ESWL) is one of the main methods of treatment of 
urolithiasis in Ukraine, which provides elimination of urinary tract calculi in most patients. At 
the same time, the process of elimination of destructed urinary tract calculi takes time; there is 
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also a risk of their incomplete elimination. In addition, even in the event of complete and uncom-
plicated elimination of urinary calculi [5, 6], there is a significantly increased risk of recurrence 
of stone formation in the following years. It means that the method of elimination of urinary tract 
stones does not affect the metabolic disorders, which manifest themselves as calculi formation. 
Thus, there is a need for accompanying therapy, which can improve efficacy of elimination of 
calculi following ESWL on the one hand and reduce the likelihood of recurrence in a long-term 
therapy on the other hand [7, 8]. The herbal drug Canephron N has a complex of effects that 
may affect both the efficacy of elimination of urinary calculi fragments following lithotripsy 
[5, 9] and non-specific factors of stone formation: decrease in urinary saturation by stone-form-
ing substances; increase in concentration of magnesium ions in urine which are natural inhib-
itors of crystallization [10]; effect on indirect factors of calculi formation (inflammation, im-
paired urodynamics, etc.). 
At this time, there is considerable experience in using Canephron N both in treatment and 
metaphylaxis of urolithiasis [11, 12]. However, there is a limited number of studies where the ability 
of Canephron N to potentiate ESWL effect and prevent the risk of UL recurrence was evaluated.
2. Aim of research
Analyse the ability of the drug Canephron N to potentiate the efficacy of extracorporeal 
shock wave lithotripsy in the treatment of patients with UL and prevent recurrent stone formation 
in the first year after complete elimination of fragments in these patients.
3. Materials and methods
Study design: our study was an open, single centre, prospective, comparative (paral-
lel group), interventional randomized study. To achieve the objective we selected two groups of 
30 patients with UL (at the age of 18 to 65 years) with diagnosed calcium oxalate urolithiasis, 
existing single stones relatively of the same size localized in the kidneys and ureters. The study 
compared treatment with the drug Canephron N (treatment group) in combination with traditional 
treatment in patients with UL by ESWL method and patients (control group) who received only the 
traditional UL treatment by ESWL method (Table 1).
Table 1
Treatment groups during the study for 6 months
Group Medical treatment Dosage Duration
Treatment group 
(n=30)
ESWL 1 ESWL session Single time
Diet Kept
Adequate fluid intake Kept
Canephron N 2 tablets/50 drops  3 times daily 6 month
Spasmolytics As prescribed During the period of  elimination of fragments
PT Daily Daily
Painkillers, spasmolytics  
if pain syndrome occurs As prescribed Situationally Single time
Control group  
(n=30)
ESWL 1 ESWL session Single time
Diet Kept
Adequate fluid intake Kept
Spasmolytics As prescribed During the period of elimina-tion of fragments
PT Daily Daily
Painkillers, spasmolytics if 
 pain syndrome occurs As directed Situationally Single time
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According to the standard of care, all patients underwent a complete urological examination 
before treatment initiation: complete blood count, urinalysis with microscopy, urine pH testing (be-
fore, during and after the treatment); blood biochemistry; plain urography (+ after the treatment); 
ultrasonography of kidneys, ureters and the bladder (before, during and after the treatment).
Study population:
Patients (men and women) from 18 to 65 years (the average age was 41.5 years) with diag-
nosed UL (calcium oxalate urolithiasis) following ESWL – 60 patients with stones relatively of the 
same size and location and preserved kidney function. The treatment and control groups consisted 
of 30 patients each (n=30). The distribution between the groups was performed by randomly num-
bered envelopes.
Inclusion criteria: The main inclusion criterion was a proven diagnosis of calcium oxalate 
urolithiasis with a single stone from 0.8 to 1.3 cm in size in the kidneys and a single stone from 
0.5 cm to 0.9 cm in the ureter; age of 18–65 years and consent to participate in the study. The chem-
ical composition of the calculus was predicted with urine microscopy, urine pH test and plain X-ray 
before treatment and with X-ray structural analysis after elimination of fragments. 
Exclusion criteria:
– Generally accepted contraindications to treatment with ESWL method;
– Long-term urinary tract obstruction by a stone and marked impairment of excretory func-
tion of the kidneys;
– Diabetes mellitus;
– Immunodeficiency;
– Severe concomitant somatic disease that may significantly affect the course of UL treat-
ment with ESWL method;
– Calculus size greater than 1.3 cm;
– Chemically another type of urolithiasis (phosphates, urates, struvites).
Study methodology
During the study period patients had 6 visits: visit 1 (Day 1) – ESWL procedure; visit 2 
(Day 7) – evaluation of elimination results of disintegrated calculi; no complications and indica-
tions for repeat procedure; visit 3 (Day 14) – evaluation of treatment results (percentage of compete 
elimination of the urinary tract fragments of the disintegrated stone; no complications); visit 4 
(Day 30) – evaluation of treatment results (percentage of complete elimination of the urinary tract 
fragments); visit 5 (Day 45) – final evaluation of treatment results (percentage of complete elimi-
nation of the urinary tract fragments); visit 6 (one year after) – evaluation of possible recurrence of 
stone formation.
From visit 1 to visit 6 the doctor evaluated:
– complaints, pain localization, severity, discomfort, urination disorders and other;
– clinical and physical examination results;
– results of complete blood count;
– results of urinalysis: urine pH test, level of leukocyturia;
– results of ultrasound of kidneys, ureters, bladder;
– plain X-ray results (if necessary).
Efficacy endpoints
The main efficacy endpoints were included complete elimination of the urinary tract calculi 
and their fragments, the need for repeat ESWL, no complications and no disease recurrence within 
one year. 
Safety criteria
No side or adverse events during the study drug administration.
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Data analysis
Data were presented using descriptive methods. The difference between two groups was 
evaluated with the help of two samples using a two-sided 95 % confidence interval (95 % CI) with 
a confidence coefficient of p≤0.05.
4. Results
The average age of the patients in the treatment group was 41 (±4.6) years; in the control 
group – 42 (±5.0) years. This means that the groups did not have any age differences. In the treat-
ment group 33.3 % of patients had calculi in the renal pelvis, 16.7 % in the renal calyx, 33.3 % 
in the proximal ureter and 6.7 % of patients in the distal ureter. The average size of stones in the 
kidneys was 1.0±0.2 cm; 0.7±0.1 cm in the ureters. In the control group, stones in the renal pelvis 
were detected in 30 % of patients; in the renal calyx – in 20 % of patients. Calculi in the proximal 
ureter were detected in 36.7 % of patients; in the distal ureter – in 13.3 % of patients. The average 
size of renal calculi was 1.0±0.3 cm, ureteral calculi – 0.7±0.2 cm. Before treatment starts, lumbar 
pain (localization of calculus) was observed in 83.3 % of patients in the treatment group and in 
80 % of patients in the control group. Leukocyturia was also observed in 40 % and 33 % of patients, 
respectively. Urine pH in the treatment group was 5.9±0.5; in the control group – 6.0±0.5. All the 
patients of both groups successfully underwent 34 and 35 ESWL sessions, respectively; the average 
number of impulses necessary for stone fragmentation was 2450±350 (in the treatment group) and 
2450±400 (in the control group). Stone disintegration following ESWL session was successful if 
there were fragments up to 4 mm, which were evaluated with the control ultrasound investigation 
and plain Xray examination, if necessary.
Elimination of destructed fragments.
During the follow-up there was a significant difference in the dynamics of elimination of 
destructed urinary calculi. This parameter is depicted in Fig. 1.
Fig. 1. Dynamics (%) of elimination of destructed urinary stones in the groups.
Despite the fact that in our study the complete elimination of destructed stone fragments 
was observed in all patients in both groups, we may conclude that this process was much faster 
in the treatment group. Thus, the complete elimination of fragments from the urinary tracts after 
14 days was 96.7 % in the treatment group. Only one patient (3.3 %) needed a longer period (up 
to 30 days) for elimination of destructed fragments. After 14 days, the complete elimination of 
fragments was observed only in 76.6 % of patients in the control group, almost 20 % less than in 
the treatment group.
In order to achieve the complete elimination of calculi, some patients needed repeated 
ESWL sessions because of the large fragments determined by ultrasound and X-ray examinations. 
Thus, the average number of EL sessions per one stone in the treatment and control groups was 
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1.13 and 1.17 sessions, respectively. However, this difference was not statistically significant and 
had the character of a tendency.
Complications following ESWL
After the EWSL procedure during elimination of urinary calculi fragments, some patients 
had lumbar pain, which in some cases had the character of renal colic. It is important to note that 
some of these complications was significantly lower in the treatment group compared with the con-
trol group in relation to the “pain and discomfort” symptom and leukocyturia. In regard to renal 
colic there was also a difference but it was not statistically significant and had the character of a 
tendency (Table 2).
Table 2
Proportion of complications following ESWL in the groups during elimination of stone fragments
No. Symptoms Treatment group n/% Control group n/ % Power
1 Lumbar pain during fragment elimination, lower abdominal pain. 7 (23 %) 13 (43.3 %) p≤0.05
2 Renal colic 2 (6.6 %) 3 (10 %) p≤0.05
3 Leukocyturia on days 7–14 3 (10 %) 7 (23 %) p≤0.05
Recurrence rate of stone formation within one year after ESWL 
Within one-year patient follow-up, recurrent stone formation after elimination of calculi 
from the urinary tracts was detected in 2 patients in the control group and no cases in the treatment 
group. However, due to the small number of studied events, it is impossible to talk about the reli-
ability of differences in relation to the incidence of recurrent stone formation between the groups.
5. Discussion
Urolithiasis is a common and economically important disease characterized by formation of 
calculi (chemically various) in different parts of the urinary system. Despite the steady increase in 
the prevalence rate of this disease, the main emphasis in modern medicine is to improve methods 
of calculi removal and, to a lesser extent, conservative treatment [13, 14]. However, combination 
of these two approaches not only could increase the efficacy of calculi removal techniques but 
also prevent recurrence of stone formation [15, 16]. The drug Canephron N fits well for the role 
of one of the major herbal components in the complex conservative UL treatment. This medical 
drug consists of a fixed combination of herbal components standardized by the composition of key 
active ingredients of herbs: centaury, lovage root and medical rosemary leaves. Such combined 
composition provides a complex effect on the kidneys and the urinary tracts that is expressed in a 
moderate diuretic [11, 17] and spasmolytic action [18] associated with the ability of the study drug 
to improve urodynamics and contribute to faster elimination of calculi [19, 20]. During this study, 
more rapid elimination of calculi fragments from the urinary tracts was also observed. At the 
end of the second week after ESWL, the percentage of patients with complete elimination was by 
20.8 % higher in the treatment group than in the control group. Also, due to these properties, there 
were fewer cases (by 46.5 %) of lumbar pain or abdominal discomfort during elimination of disin-
tegrated stone fragments in the treatment group. Anti-inflammatory action of herbal components 
in Canephron N [11] is of great importance, which contributes to rapid regression of consequences 
of the urinary tract mucosa injury and eradication of leukocyturia. This is supported by data of our 
study when we observed that the frequency of leukocyturia in the treatment group was 56.5 % less 
than in the control group. Furthermore, it is very important for treatment goals that Canephron N 
has the ability to inhibit pathogenetic factor of urinary system pathogens which helps to prevent 
the occurrence of inflammatory process in the urinary tracts during elimination of urinary calculi 
fragments. With respect to prevention of recurrent stone formation, the ability of Canephron N to 
influence the key non-specific factors of stone formation is of great value: urine saturation with 
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crystal-forming substances, increase in the concentration of magnesium ions in urine (natural in-
hibitor of crystallisation), influence on the infectious and inflammatory factors of urinary calculi 
formation. Therefore, it is clear that the use of Canephron N in the complex therapy following 
ESWL accelerates elimination of fragments of disintegrated calculi from the urinary tracts regard-
less of the level of their original location and reduces the number of such complications as lower 
abdominal pain and discomfort, renal colic attacks. 
6. Conclusion
1. Canephron N is effective and safe for the treatment of patients with urolithiasis including 
those treated with extracorporeal shock wave lithotripsy. 
2. Treatment with Canephron N contributes to faster and safer elimination of destructed 
calculi fragments and reduces risk.
3. Treatment with Canephron N for 6 months contributes to prevent of recurrent stone 
formation.
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